Search Result

Results for "

Vonoprazan

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bacterial (4) Drug Intermediate (5) Drug Metabolite (1) Isotope-Labeled Compounds (4) Proton Pump (5) Reference Standards (2)
By Research Areas:	Cancer (2) Endocrinology (2) Infection (5) Inflammation/Immunology (1) Metabolic Disease (1)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Nombre del producto	Target	Áreas de investigación	Chemical Structure

HY-15295

Vonoprazan Fumarate Maximum Cited Publications 6 Publications Verification TAK-438	Proton Pump	Infection Inflammation/Immunology
Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-100007

*Vonoprazan* Maximum Cited Publications 6 Publications Verification TAK-438 free base	Proton Pump Bacterial	Infection
Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .

HY-W728503S

*N-Nitroso Vonoprazan-13C,d3*	Isotope-Labeled Compounds	Infection
N-Nitroso Vonoprazan-sup>13C,d₃ is the sup>13C- and deuterium labeled N-Nitroso Vonoprazan. N-Nitroso Vonoprazan is an impurity of Vonoprazan .

HY-100007A

Vonoprazan hydrochloride Maximum Cited Publications 6 Publications Verification TAK-438 hydrochloride	Proton Pump Bacterial	Infection Endocrinology Cancer
Vonoprazan hydrochloride, a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan hydrochloride inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan hydrochloride is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan hydrochloride can be used for eradication of Helicobacter pylori .

HY-15295R

Vonoprazan Fumarate (Standard) TAK-438 (Standard)	Proton Pump Reference Standards	Metabolic Disease Cancer
Vonoprazan (Fumarate) (Standard) is the analytical standard of Vonoprazan (Fumarate). This product is intended for research and analytical applications. Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-Z3421S1

Vonoprazan-d4 fumarate	Isotope-Labeled Compounds	Others
Vonoprazan-d₄ (fumarate) is deuterium labeled 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine fumarate (Vonoprazan Impurity).

HY-Z3421S

Vonoprazan-d3 fumarate	Isotope-Labeled Compounds	Others
Vonoprazan-d₃ fumarate is the deuterium labeled Vonoprazan fumarate (HY-15295). Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-100007R

Vonoprazan (Standard) TAK-438 (Standard)	Reference Standards Proton Pump Bacterial	Endocrinology
Vonoprazan (Standard) is the analytical standard of Vonoprazan. This product is intended for research and analytical applications. Vonoprazan (TAK-438 free base), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan inhibits H ⁺,K ⁺-ATPase activity in porcine gastric microsomes with an IC₅₀ of 19 nM at pH 6.5. Vonoprazan is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease. Vonoprazan can be used for eradication of Helicobacter pylori .

HY-W096504

Vonoprazan impurity 4	Drug Intermediate	Others
Vonoprazan impurity 4 is an impurity of Vonoprazan (HY-100007).

HY-Z3759

Vonoprazan impurity 7	Drug Intermediate	Others
Vonoprazan impurity 7 is an impurity of Vonoprazan (HY-100007).

HY-Z2106S

Vonoprazan impurity 11-d5 fumarate	Drug Metabolite Isotope-Labeled Compounds	Others
Vonoprazan impurity 11-d₅ (fumarate) is deuterium labeled 1-(5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-((5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)methyl)-N-methylmethanamine (Vonoprazan Impurity).

HY-Z2063

Vonoprazan impurity 6	Drug Intermediate	Others
Vonoprazan impurity 6 is an impurity of Vonoprazan (HY-100007).

HY-Z2335

Vonoprazan impurity 1	Drug Intermediate	Others
Vonoprazan impurity 1 is an impurity of Vonoprazan (HY-100007).

HY-Z3136

Vonoprazan impurity 46	Drug Intermediate	Others
Vonoprazan impurity 46 is an impurity of Vonoprazan (HY-100007).

HY-181038

*Rifabutin-vonoprazan* conjugate 1**	Bacterial	Infection
Rifabutin-vonoprazan conjugate 1 is an orally active acid-responsive bifunctional molecule. Rifabutin-vonoprazan conjugate 1 exhibits anti-Helicobacter pylori activity (MIC ≤ 0.125 μg/mL) and acid-suppressive effects (acid inhibition rate > 85% at a dose of 2 mg/kg). Rifabutin-vonoprazan conjugate 1 also demonstrates anti-ulcer activity. Rifabutin-vonoprazan conjugate 1 can be used in research related to Helicobacter pylori infection and gastric ulcer .

Cat. No.	Nombre del producto	Chemical Structure

HY-W728503S

*N-Nitroso Vonoprazan-13C,d3*
N-Nitroso Vonoprazan-sup>13C,d₃ is the sup>13C- and deuterium labeled N-Nitroso Vonoprazan. N-Nitroso Vonoprazan is an impurity of Vonoprazan .

HY-Z3421S1

Vonoprazan-d4 fumarate
Vonoprazan-d₄ (fumarate) is deuterium labeled 1-(5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-methylmethanamine fumarate (Vonoprazan Impurity).

HY-Z3421S

Vonoprazan-d3 fumarate
Vonoprazan-d₃ fumarate is the deuterium labeled Vonoprazan fumarate (HY-15295). Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

Vonoprazan-d3 fumarate

Vonoprazan-d₃ fumarate is the deuterium labeled Vonoprazan fumarate (HY-15295). Vonoprazan Fumarate (TAK-438), a proton pump inhibitor (PPI), is a potent and orally active potassium-competitive acid blocker (P-CAB), with antisecretory activity. Vonoprazan Fumarate inhibits H+,K+-ATPase activity in porcine gastric microsomes with an IC50 of 19 nM at pH 6.5. Vonoprazan Fumarate is developed for the research of acid-related diseases, such as gastroesophageal reflux disease and peptic ulcer disease .

HY-Z2106S

Vonoprazan impurity 11-d5 fumarate
Vonoprazan impurity 11-d₅ (fumarate) is deuterium labeled 1-(5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)-N-((5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl)methyl)-N-methylmethanamine (Vonoprazan Impurity).

Consulta en línea

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Saludo			Country or Region *
Nombre del solicitante *			Nombre de la Organizaciòn *
Department *
Direcciòn del E-mail *			Nombre del producto *
Cat. No.			Requested quantity *
Número de teléfono *
Observaciones

Consulta en línea

Inquiry Information

Nombre del producto:
Cat. No.:
Cantidad:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
E-mail *

	Sorry, but the email address you supplied was invalid.